Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Blood advances - 10 Feb 2026

Tam Constantine S, Anderson Mary Ann, Šimkovič Martin, Ghia Paolo, Flinn Ian W, Laribi Kamel, Opat Stephen, Cull Gavin, Munir Talha, Österborg Anders, Tedeschi Alessandra, Wang Megan, Szeto Andy, Allewelt Heather, Salmi Tommi, Li Jessica, Xu Linlin, Wu Kenneth, Vezan Remus, Shadman Mazyar, Brown Jennifer R

Abstract excerpt

ABSTRACT: Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who harbor del(17p) and/or tumor protein p53 (TP53) mutations represent a high-risk population with a historically poor prognosis. To assess zanubrutinib efficacy and safety outcomes in patients with CLL/SLL with del(17p) and/or TP53 mutations (N = 301; n = 132, treatment-naive [TN]; n = 169, relapsed/refractory [R/R]), data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Chromosome Deletion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 17

Share to Clinical Trials as Topic

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Piperidines

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 40829104
DOI: 10.1182/bloodadvances.2025015986
PMCID: PMC12870863

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.PMID 40829104Read ↗

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.Semantic proximity Read ↗

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.Semantic proximity Read ↗

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.Semantic proximity Read ↗

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Semantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Semantic proximity Read ↗

17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.Semantic proximity Read ↗

How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?Semantic proximity Read ↗

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.Semantic proximity Read ↗

Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.Semantic proximity Read ↗

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.